Echoing Pfizer, OSI To Put IGF-1R Candidate In Phase III
This article was originally published in The Pink Sheet Daily
Company plans to piggyback the potential lung-cancer drug – combined with Tarceva – on current Phase I study, as investors await SATURN and ATLAS details at ASCO.
You may also be interested in...
Combined with SATURN data, new results may enable sNDA approval in first-line maintenance without overall survival numbers.
CHICAGO - With 22 oncology compounds in clinical studies, firm initiates two Phase III studies since Jan. 1; plans to start another five before year-end.
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf